UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mutation clearance and complete radiologic resolution of immunotherapy relapsed metastatic melanoma after treatment with nivolumab and olaparib in a patient with homologous recombinant deficiency: any role for PARP inhibitors and checkpoint blockade?

Annals of oncology, 2021-02, Vol.32 (2), p.279-280

2021

Volltextzugriff (PDF)

Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4

Leukemia, 2012-01, Vol.26 (1), p.34-53

2012

Volltextzugriff (PDF)

Effect of Single-Agent Concurrent Chemotherapy on Survival in Anaplastic Oligodendroglioma: A Review of the National Cancer Data Base

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.E76-E77

2016

Volltextzugriff (PDF)

NCI 9922: Phase II study of ibrutinib in treatment-refractory distant metastatic cutaneous melanoma (DMCM)

Annals of oncology, 2018-10, Vol.29, p.viii453-viii453

2018

Volltextzugriff (PDF)

Imaging Changes Following Proton Radiation Therapy in Adult Diffuse Gliomas

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.E106-E106

2016

Volltextzugriff (PDF)

1098P Mechanisms of recurrence following mRNA-4157 (V940) plus pembrolizumab or pembrolizumab alone in resected melanoma from the mRNA-4157-P201 (KEYNOTE-942) trial

Annals of oncology, 2024-09, Vol.35, p.S727-S728

2024

Volltextzugriff (PDF)

278O Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295

Annals of oncology, 2022-09, Vol.33, p.S666

2022

Volltextzugriff (PDF)

LBA49 mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response

Annals of oncology, 2023-10, Vol.34, p.S1288-S1289

2023

Volltextzugriff (PDF)

814P Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3

Annals of oncology, 2022-09, Vol.33, p.S918-S919

2022

Volltextzugriff (PDF)

Clinical Outcomes of Reirradiation in IDH-Mutant Astrocytomas and 1p/19q Codeleted Oligodendrogliomas

International journal of radiation oncology, biology, physics, 2018-11, Vol.102 (3), p.e342-e342

2018

Volltextzugriff (PDF)

Brain Metastases in Metastatic Cutaneous Melanoma: Patterns of Care and Clinical Outcomes in the Era of Immunotherapy and Targeted Therapy

International journal of radiation oncology, biology, physics, 2021-11, Vol.111 (3), p.e565-e566

2021

Volltextzugriff (PDF)

1268PNCI 9922: Phase II study of ibrutinib in treatment-refractory distant metastatic cutaneous melanoma (DMCM)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Prospective phase II study of tumor response assessment by CT and FDG-PET/CT following 8 weekly doses of cetuximab in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.5569-5569

2011

Volltextzugriff (PDF)

A Phase 1 study of fianlimab in combination with cemiplimab in patients with anti–PD-1/L1-experienced cutaneous squamous cell carcinoma

EJC skin cancer, 2024, Vol.2, p.100213, Article 100213

2024

Volltextzugriff (PDF)

A-305 - A Phase 1 study of fianlimab in combination with cemiplimab in patients with anti–PD-1/L1-experienced cutaneous squamous cell carcinoma

EJC skin cancer, 2024, Vol.2

2024

Volltextzugriff (PDF)

Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy

Cancer discovery, 2016-11, Vol.6 (11), p.1230-1236

2016

Volltextzugriff (PDF)

Use of extracranial radiation therapy in metastatic melanoma patients receiving immunotherapy

Radiotherapy and oncology, 2018-05, Vol.127 (2), p.310-317

2018

Volltextzugriff (PDF)

Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations

Journal of clinical oncology, 2023-01, Vol.41 (3), p.618-628

2023

Volltextzugriff (PDF)

A Phase 1/2 Study of Disulfiram and Copper With Concurrent Radiation Therapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma

International journal of radiation oncology, biology, physics, 2024-11, Vol.120 (3), p.738-749

2024

Volltextzugriff (PDF)

Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.2058-2058

2022

Volltextzugriff (PDF)

(P60) Targeting Radiation Therapy to Soft Tissue Lesions Prior to the Start of Immunotherapy Improves Survival in Extracranial Metastatic Melanoma

International journal of radiation oncology, biology, physics, 2018-06, Vol.101 (2), p.E43-E44

2018

Volltextzugriff (PDF)

Safety and efficacy study of retifanlimab and epacadostat in combination with radiation and bevacizumab in patients with recurrent glioblastoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS2070-TPS2070

2021

Volltextzugriff (PDF)

A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6

Journal of the American Academy of Dermatology, 2024-09

2024

Volltextzugriff (PDF)

A phase I/II study to evaluate the safety and efficacy of a novel long-acting interleukin-7, NT-I7, for patients with newly diagnosed high-grade gliomas after chemoradiotherapy: The interim result of the phase I data

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2040-2040

2021

Volltextzugriff (PDF)

A TITE-CRM phase I/II study of disulfiram and copper with concurrent radiation therapy and temozolomide for newly diagnosed glioblastoma

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.2033-2033

2019

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieNeuro-Oncology Practice

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(9)
Oncology
(9)
Science & Technology
(9)
Humans
(5)
Immunotherapy
(4)
Chemotherapy
(3)
Clinical Neurology
(3)
Neurosciences & Neurology
(3)
Clinical Investigations
(2)
Gbm
(2)
Glioblastoma - Drug Therapy
(2)
Hematology, Oncology And Palliative Medicine
(2)
Male
(2)
Medicine
(2)
Medicine & Public Health
(2)
Mutation
(2)
Ncdb
(2)
Radiation Therapy
(2)
Radiology
(2)
Radiology, Nuclear Medicine & Medical Imaging
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Mutation clearance and complete radiologic resolution of immunotherapy relapsed metastatic melanoma after treatment with nivolumab and olaparib in a patient with homologous recombinant deficiency: any role for PARP inhibitors and checkpoint blockade?

Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4

Effect of Single-Agent Concurrent Chemotherapy on Survival in Anaplastic Oligodendroglioma: A Review of the National Cancer Data Base

NCI 9922: Phase II study of ibrutinib in treatment-refractory distant metastatic cutaneous melanoma (DMCM)

Imaging Changes Following Proton Radiation Therapy in Adult Diffuse Gliomas

1098P Mechanisms of recurrence following mRNA-4157 (V940) plus pembrolizumab or pembrolizumab alone in resected melanoma from the mRNA-4157-P201 (KEYNOTE-942) trial

278O Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295

LBA49 mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response

814P Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3

Clinical Outcomes of Reirradiation in IDH-Mutant Astrocytomas and 1p/19q Codeleted Oligodendrogliomas

Brain Metastases in Metastatic Cutaneous Melanoma: Patterns of Care and Clinical Outcomes in the Era of Immunotherapy and Targeted Therapy

1268PNCI 9922: Phase II study of ibrutinib in treatment-refractory distant metastatic cutaneous melanoma (DMCM)

Prospective phase II study of tumor response assessment by CT and FDG-PET/CT following 8 weekly doses of cetuximab in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC)

A Phase 1 study of fianlimab in combination with cemiplimab in patients with anti–PD-1/L1-experienced cutaneous squamous cell carcinoma

A-305 - A Phase 1 study of fianlimab in combination with cemiplimab in patients with anti–PD-1/L1-experienced cutaneous squamous cell carcinoma

Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy

Use of extracranial radiation therapy in metastatic melanoma patients receiving immunotherapy

Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations

A Phase 1/2 Study of Disulfiram and Copper With Concurrent Radiation Therapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma

Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295

(P60) Targeting Radiation Therapy to Soft Tissue Lesions Prior to the Start of Immunotherapy Improves Survival in Extracranial Metastatic Melanoma

Safety and efficacy study of retifanlimab and epacadostat in combination with radiation and bevacizumab in patients with recurrent glioblastoma

A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6

A phase I/II study to evaluate the safety and efficacy of a novel long-acting interleukin-7, NT-I7, for patients with newly diagnosed high-grade gliomas after chemoradiotherapy: The interim result of the phase I data

A TITE-CRM phase I/II study of disulfiram and copper with concurrent radiation therapy and temozolomide for newly diagnosed glioblastoma

Aktive Filter

Suchergebnisse filtern